GlaxoSmithKline PlcEurope's biggest drugmaker, said the U.S. Department of Justice was investigating whether certain of its pricing policies violated Medicaid rules.
The company, which disclosed the probe in a filing with the Securities and Exchange Commission late on Tuesday, said it was cooperating in the investigation by government attorneys.
GSK said it had provided documents and information about so-called nominal pricing arrangements for a number of products.
The attorneys involved in the case are the same ones that are investigating whether a number of companies, including GSK, inflated average wholesale prices of drugs, which are used to determine how much Medicaid pays for products.
Under regulations governing Medicaid -- the U.S. government's health plan for the poor -- drugmakers are required to report the lowest price of a medicine.
The Department of Justice is now studying whether some of GSK's nominal pricing arrangements may have violated civil statutes or laws.
